hotspot -WSS

hotspot

author：comprehensive 2025-10-03 00:06:40 - browse：429

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Why depression after traumatic brain injury is distinct

WSS

Elizabeth Holmes banned from government health programs

FDA clears AI tool for detecting skin cancer

Independent physicians launch a new lobbying group

Think you might have Covid

Elizabeth Holmes banned from government health programs

Think you might have Covid

focus

hotspot

focus

How to save PrEP access — and even expand it

Why scientists need input from humanists on sensitive research

Anesthesiologist group: stop taking Ozempic before surgery

Why depression after traumatic brain injury is distinct

BioMarin wins approval for gene therapy to treat hemophilia A

Steward Health Care Massachusetts hospitals face fiscal disaster

How one medical school became remarkably diverse

WuXi out of biotech trade group, U.S. and China relations to blame

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Eli Lilly, Pfizer, and others want in on the online prescription market

leisure time

First U.S. drug developed to treat liver disease MASH is approved

Test for long Covid? Researchers find new clue in blood samples

Steward Health Care Massachusetts hospitals face fiscal disaster

Change Healthcare outage fallout shows need for new oversight

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Readout Newsletter: Bristol, Sangamo, Gilead, and more

entertainment

leisure time

knowledge

focus